Adrenocorticosteroid Pharmacology — Chapter 28 | Introduction to Medical Pharmacology

Section 01

Adrenal Cortex Zones and Steroid Biosynthesis

Zonal organization of the adrenal cortex, the cholesterol-to-steroid pathway, rate-limiting steps, and the clinical relevance of key biosynthetic enzymes

The adrenal cortex produces three classes of steroid hormones from a shared cholesterol precursor. Each class originates in a distinct cortical zone under different regulatory control. This zonal and enzymatic organization explains how drugs that inhibit specific biosynthetic enzymes produce selective effects on steroid output.

Cortical Zones and Their Products

The adrenal cortex is organized into three concentric zones. The outermost zona glomerulosa produces aldosterone and is regulated primarily by the renin-angiotensin-aldosterone system and serum potassium. The middle zona fasciculata is the largest zone and produces cortisol under the control of adrenocorticotropic hormone from the anterior pituitary. The innermost zona reticularis produces adrenal androgens, principally dehydroepiandrosterone and its sulfate ester, also under adrenocorticotropic hormone control.

Zone specificity is determined by enzyme expression. The zona glomerulosa expresses aldosterone synthase (CYP11B2) but not the 17-alpha-hydroxylase activity of CYP17A1, making it capable of producing aldosterone but not cortisol. The zona fasciculata expresses CYP17A1 and CYP11B1 but not CYP11B2, producing cortisol but not aldosterone. The zona reticularis expresses CYP17A1 with high lyase activity to produce dehydroepiandrosterone.

The Biosynthetic Pathway

All steroid synthesis begins with cholesterol, derived primarily from low-density lipoprotein uptake. The rate-limiting step is transport of cholesterol from the outer to the inner mitochondrial membrane, mediated by the steroidogenic acute regulatory (StAR) protein. Adrenocorticotropic hormone acutely upregulates StAR expression through a cyclic adenosine monophosphate-dependent mechanism, which is how adrenocorticotropic hormone stimulation rapidly increases cortisol output.

Once at the inner membrane, CYP11A1 (the cholesterol side-chain cleavage enzyme) converts cholesterol to pregnenolone, the committed step. Pregnenolone then enters parallel pathways. In the zona fasciculata, CYP17A1 hydroxylates pregnenolone to 17-hydroxypregnenolone, which is further processed to 17-hydroxyprogesterone. CYP21A2 (21-hydroxylase) then converts 17-hydroxyprogesterone to 11-deoxycortisol, and CYP11B1 (11-beta-hydroxylase) completes cortisol synthesis.

21-Hydroxylase Deficiency: Most Common Form of Congenital Adrenal Hyperplasia

CYP21A2 deficiency blocks the conversion of 17-hydroxyprogesterone to 11-deoxycortisol. Because cortisol cannot be made, adrenocorticotropic hormone remains elevated, driving substrate accumulation proximal to the block. The accumulated 17-hydroxyprogesterone is shunted into androgen synthesis, producing cortisol deficiency, variable aldosterone deficiency, and androgen excess. The degree of virilization in females and salt-wasting depends on mutation severity. Elevated 17-hydroxyprogesterone is the diagnostic marker.

Key Enzymes

Biosynthetic Enzymes and Their Clinical Significance

StAR protein — rate-limiting cholesterol transport; acutely upregulated by adrenocorticotropic hormone via cyclic adenosine monophosphate; deficient in congenital lipoid adrenal hyperplasia
CYP11A1 — cholesterol to pregnenolone; committed step; not a drug target in current clinical use
CYP17A1 — 17-alpha-hydroxylase and lyase activities; absent in zona glomerulosa, explaining why aldosterone cannot be produced there; targeted by abiraterone in prostate cancer
CYP21A2 (21-hydroxylase) — 17-hydroxyprogesterone to 11-deoxycortisol; deficiency = most common cause of congenital adrenal hyperplasia; elevated 17-hydroxyprogesterone is the diagnostic marker
CYP11B1 (11-beta-hydroxylase) — 11-deoxycortisol to cortisol; inhibited by metyrapone (used in Cushing syndrome diagnosis and management)
CYP11B2 (aldosterone synthase) — zona glomerulosa only; regulated by angiotensin II and potassium, not adrenocorticotropic hormone; not inhibited by standard glucocorticoid drugs

Adrenal steroid biosynthesis pathway from cholesterol to cortisol and aldosterone — Figure 1. Adrenal steroid biosynthesis pathway. StAR protein mediates the rate-limiting cholesterol transport step. CYP21A2 (21-hydroxylase) deficiency is the most common cause of congenital adrenal hyperplasia. CYP11B1 is the target of metyrapone.

Section 02

Glucocorticoid Receptor Mechanism

Genomic transactivation, tethered transrepression of nuclear factor kappa-B and activator protein-1, and the clinical significance of these two distinct signaling modes

Glucocorticoids act primarily through the glucocorticoid receptor, a cytoplasmic ligand-activated transcription factor. Two distinct signaling modes account for the therapeutic and adverse effect profiles of glucocorticoid therapy: transactivation of metabolic genes drives most adverse effects, while transrepression of inflammatory transcription factors drives most anti-inflammatory benefit.

Receptor Activation and Nuclear Translocation

The unliganded glucocorticoid receptor resides in the cytoplasm bound to a chaperone complex that includes heat shock protein 90 (HSP90), which holds the receptor in a conformation competent for ligand binding. When a glucocorticoid binds the receptor, a conformational change releases the receptor from the complex and triggers translocation to the nucleus, where it acts as a transcription factor.

Genomic Transactivation

In the nucleus, activated glucocorticoid receptor homodimers bind glucocorticoid response element sequences in the promoters of target genes and recruit coactivator complexes that enhance transcription. This transactivation drives expression of genes that produce most adverse metabolic effects: gluconeogenic enzymes (causing hyperglycemia), muscle-specific ubiquitin ligases (causing muscle atrophy), and suppression of osteocalcin synthesis (contributing to osteoporosis).

Tethered Transrepression

The anti-inflammatory actions of glucocorticoids depend on a mechanistically distinct process. Rather than binding directly to DNA, glucocorticoid receptor monomers physically interact with and inhibit pro-inflammatory transcription factors, principally nuclear factor kappa-B and activator protein-1. Nuclear factor kappa-B normally drives transcription of cyclooxygenase-2, inducible nitric oxide synthase, multiple interleukins, and adhesion molecules. By binding the p65 subunit of nuclear factor kappa-B, the glucocorticoid receptor blocks transcription of these pro-inflammatory targets without requiring glucocorticoid response element binding.

Glucocorticoids also induce transcription of the inhibitory protein I-kappa-B, which sequesters nuclear factor kappa-B in the cytoplasm, providing a second layer of nuclear factor kappa-B suppression. Similarly, glucocorticoid receptor binding to activator protein-1 (a heterodimer of c-Fos and c-Jun) reduces transcription of matrix metalloproteinases and additional cytokines.

Transactivation vs. Transrepression: Why the Distinction Matters

Adverse metabolic effects (hyperglycemia, osteoporosis, muscle atrophy, skin thinning) are driven primarily by glucocorticoid response element-dependent transactivation. Anti-inflammatory effects are driven primarily by tethered transrepression of nuclear factor kappa-B and activator protein-1. This distinction has motivated decades of research into agents that favor transrepression over transactivation, though no currently available drug achieves this separation in patients. Budesonide achieves a partial pharmacokinetic separation by limiting systemic transactivation through high first-pass hepatic metabolism while maintaining local anti-inflammatory transrepression in the gut or airway.

Two-panel diagram comparing glucocorticoid receptor transactivation and transrepression — Figure 2. Glucocorticoid receptor signaling modes. Transactivation (left) drives most adverse metabolic effects through glucocorticoid response element binding. Tethered transrepression of nuclear factor kappa-B (right) drives most anti-inflammatory benefit without direct DNA contact.

Section 03

HPA Axis Physiology and Suppression

Circadian cortisol secretion, feedback regulation, the pharmacological basis of glucocorticoid-induced adrenal insufficiency, and the clinical significance of dosing timing

The hypothalamic-pituitary-adrenal axis regulates cortisol secretion and is suppressed by exogenous glucocorticoids in a dose- and duration-dependent manner. Understanding this suppression is inseparable from understanding the risks of steroid therapy and the rationale for tapering and stress-dose supplementation.

Axis Physiology and Circadian Rhythm

The hypothalamus releases corticotropin-releasing hormone into the portal circulation, stimulating the anterior pituitary to secrete adrenocorticotropic hormone, which in turn drives cortisol synthesis in the zona fasciculata. Cortisol feeds back negatively to suppress both corticotropin-releasing hormone and adrenocorticotropic hormone secretion, completing the regulatory loop.

Cortisol secretion follows a circadian rhythm driven by the suprachiasmatic nucleus. Levels peak 30 to 60 minutes after awakening (the cortisol awakening response) and fall through the day, reaching their nadir around midnight. This rhythm has a direct clinical implication: once-daily glucocorticoid doses given in the morning produce less total hypothalamic-pituitary-adrenal axis suppression than the same dose given in the evening, because morning dosing adds to an already-elevated cortisol level that has partially suppressed the axis, whereas evening dosing suppresses the nighttime adrenocorticotropic hormone surge that drives the next morning peak.

Morning Dosing Rule

Once-daily oral glucocorticoids should be taken in the morning (7:00 to 8:00 AM). This exploits the normal circadian pattern: the axis is already partially suppressed by endogenous cortisol at this time, so the incremental suppression added by an exogenous morning dose is minimized. Evening dosing suppresses the nighttime adrenocorticotropic hormone surge with substantially greater cumulative effect on hypothalamic-pituitary-adrenal axis function. Patients must be counseled specifically about timing, not simply told to take the medication once daily.

Glucocorticoid-Induced Adrenal Insufficiency

Persistently elevated exogenous glucocorticoid levels suppress corticotropin-releasing hormone and adrenocorticotropic hormone transcription through glucocorticoid receptor-mediated repression of the respective gene promoters. Prolonged suppression leads to adrenocortical atrophy. The axis retains basal function at lower suppression, but the stress response is blunted.

As a general guide: doses below a prednisone equivalent of 5 mg per day rarely cause clinically significant suppression at any duration. Doses above 20 mg per day for more than three weeks cause substantial suppression. Duration matters as much as dose — the same cumulative amount given over a longer period causes more suppression than the same amount given over a shorter course.

Clinical Risk

Adrenal Crisis: Recognition and Immediate Management

Trigger: physiological stress (infection, surgery, vomiting) in a patient with suppressed hypothalamic-pituitary-adrenal axis who cannot mount a cortisol stress response
Features: severe hypotension or shock disproportionate to apparent cause, nausea, vomiting, fever, hyponatremia; hyperkalemia more prominent in primary adrenal insufficiency
Treatment: hydrocortisone 100 mg intravenous bolus immediately, then 200 mg over 24 hours by infusion; aggressive intravenous saline; treat precipitating cause
Do not delay treatment: if adrenal crisis is suspected, give hydrocortisone before laboratory confirmation; draw cortisol and adrenocorticotropic hormone before the dose for retrospective confirmation
Sick-day rule: double or triple oral glucocorticoid dose during febrile illness or stress; use intramuscular hydrocortisone 100 mg if unable to take oral medication

Section 04

Comparative Pharmacokinetics of Clinical Glucocorticoids

Anti-inflammatory and mineralocorticoid potency equivalents, biologic duration vs. plasma half-life, hepatic metabolism, and the pharmacokinetic basis of agent selection

The choice among hydrocortisone, prednisone, methylprednisolone, dexamethasone, and budesonide is grounded in their distinct potency ratios, biologic durations of action, mineralocorticoid activity, and routes of metabolism. These properties determine which agent is appropriate for which clinical context.

The Plasma Half-Life / Biologic Duration Distinction

All glucocorticoids share a critical pharmacokinetic feature: their biologic duration of action substantially exceeds their plasma half-life. This dissociation occurs because glucocorticoid receptor-mediated changes in gene transcription persist after plasma concentrations have fallen. Hydrocortisone has a plasma half-life of 60 to 90 minutes but produces effects lasting 8 to 12 hours. Prednisone has a plasma half-life of 2 to 3 hours but a biologic duration of 18 to 36 hours. This means once-daily dosing is pharmacologically sufficient even for short-acting agents.

Prednisone Requires Hepatic Activation

Prednisone is an inactive prodrug converted to prednisolone by 11-beta-hydroxysteroid dehydrogenase type 1 in the liver. In patients with severe hepatic insufficiency, this conversion is impaired and prednisolone is preferred because it requires no activation. For patients with normal liver function, prednisone and prednisolone are clinically interchangeable.

CYP3A4 Drug Interactions

All systemic glucocorticoids are metabolized primarily by cytochrome P450 3A4. Cytochrome P450 3A4 inducers (rifampin, phenytoin, carbamazepine, phenobarbital) accelerate glucocorticoid metabolism and can reduce plasma concentrations enough to cause loss of therapeutic effect or, in dependent patients, adrenal crisis. Cytochrome P450 3A4 inhibitors (ketoconazole, ritonavir and other protease inhibitors, clarithromycin) increase glucocorticoid concentrations and can cause iatrogenic Cushing syndrome even at standard doses. Patients on ritonavir-boosted antiretroviral regimens who receive fluticasone-containing inhaled corticosteroids are at particular risk for this interaction; beclomethasone is the preferred alternative in this population because it is not a cytochrome P450 3A4 substrate.

Potency Comparison

Clinical Glucocorticoids: Potency, Duration, and Use

Hydrocortisone — anti-inflammatory potency 1x; mineralocorticoid activity 1x; equivalent dose 20 mg; biologic duration 8–12 h. Use: physiological replacement, adrenal crisis, short-term intravenous therapy
Prednisone / Prednisolone — anti-inflammatory 4x; mineralocorticoid 0.8x; equivalent dose 5 mg; biologic duration 18–36 h. Use: most oral anti-inflammatory indications; prednisone is a prodrug requiring hepatic activation
Methylprednisolone — anti-inflammatory 5x; negligible mineralocorticoid activity; equivalent dose 4 mg; biologic duration 18–36 h. Use: intravenous pulse therapy; preferred when sodium retention must be avoided
Dexamethasone — anti-inflammatory 25–30x; no mineralocorticoid activity; equivalent dose 0.75 mg; biologic duration 36–54 h. Use: cerebral edema, fetal lung maturation, COVID-19-related acute respiratory distress syndrome (RECOVERY trial), anti-emesis, diagnostic suppression testing. Avoid for chronic therapy because of prolonged hypothalamic-pituitary-adrenal axis suppression
Budesonide — high topical anti-inflammatory potency; approximately 85–90% first-pass hepatic inactivation limits systemic bioavailability to 10–15%. Use: inhaled (asthma, chronic obstructive pulmonary disease), oral controlled-release (Crohn disease, microscopic colitis), intranasal (allergic rhinitis). Preferred when local delivery makes pharmacokinetic steroid-sparing feasible

Suggested References

Author / Organization	Title	Source
Miller WL, Auchus RJ	The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders	Endocr Rev. 2011;32(1):81–151
Stocco DM	StAR protein and the regulation of steroid hormone biosynthesis	Annu Rev Physiol. 2001;63:193–213
Chrousos GP	Adrenocorticosteroids and adrenocortical antagonists. In: Katzung BG, ed. Basic and Clinical Pharmacology, 14th ed.	McGraw-Hill; 2018:687–710
Barnes PJ	Glucocorticosteroids: current and future directions	Br J Pharmacol. 2011;163(1):29–43
Stahn C, Buttgereit F	Genomic and nongenomic effects of glucocorticoids	Nat Clin Pract Rheumatol. 2008;4(10):525–533
Rhen T, Cidlowski JA	Antiinflammatory action of glucocorticoids — new mechanisms for old drugs	N Engl J Med. 2005;353(16):1711–1723
Debono M et al.	Modified-release hydrocortisone to provide circadian cortisol profiles	J Clin Endocrinol Metab. 2009;94(5):1548–1554
Crowley RK et al.	Clinical insights into adrenal insufficiency: low-dose ACTH stimulation test versus insulin tolerance test	Clin Endocrinol (Oxf). 2010;73(4):461–466
Liu D et al.	A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy	Allergy Asthma Clin Immunol. 2013;9(1):30
Czock D et al.	Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids	Clin Pharmacokinet. 2005;44(1):61–98
Henzen C et al.	Suppression and recovery of adrenal response after short-term, high-dose glucocorticoid treatment	Lancet. 2000;355(9203):542–545